I recently gave an interview to Jo Cavallo, a journalist who is writing a story for a national medical magazine about the dilemma of paying for new targeted therapies against cancer. She asked that I post the following request for interview:
Interview Request
I'm writing a magazine story about the high cost of targeted cancer drugs and I'm looking for cancer patients to interview who have either refused treatment because they can't afford their insurance co-payment
or don't have health insurance at all and can't get the drugs. If you're interested in being interviewed, please e-mail me at jcava15579@aol.com.
If you know of a patient who has had such difficulty please email Ms. Cavallo. Thanks.
- Log in to post comments
More like this
(NOTE: The videos of Robert O. Young's interview with Kim Tinkham have been removed, as I predicted in this post that they would be. Fortunately, I downloaded copies before he managed to do that. Part 6 appears to be still there--for now.)
(NOTE ADDED 12/7/2010: Kim Tinkham has died of what was…
Saturday, I thought that I knew what I'd be writing about for Monday, which, I've learned from my two and a half years of blogging, is a great thing when it happens. A certain Libertarian comic had decided that he wanted to argue some more about secondhand smoke and indoor smoking bans, starting a…
We get hate mail. Or I do. True, I don't get an inordinate amount of hate mail, but I do get some. A lot of the time, it's rather boring and predictable, which is why I don't often respond to it on the blog, although sometimes against my better judgment I respond by e-mail. That happens less and…
Over the last two Mondays, I've been writing about an unproven cancer therapy that I hadn't really heard much about before. The cancer treatment is called Rigvir; it is manufactured in Latvia and marketed primarily through a Latvian entity called the International Virotherapy Center (IVC).
To recap…
I suggest looking at The Wall Street Journal's "The Most Expensive Drugs" series (late 2005 to early 2006). These articles featured several patients who were refusing treatment because of the extraordinarily high cost of treatment.